Echo Therapeutics (Echo Therapeutics) Total Inventories : $0.00 Mil (As of Sep. 2016)

View and export this data going back to 1997. Start your Free Trial

What is Echo Therapeutics Total Inventories?

Echo Therapeutics's total inventories for the quarter that ended in Sep. 2016 was $0.00 Mil. Echo Therapeutics's average total inventories from the quarter that ended in Jun. 2016 to the quarter that ended in Sep. 2016 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Echo Therapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2016 was $-0.62.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Echo Therapeutics Total Inventories Historical Data

The historical data trend for Echo Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Echo Therapeutics Total Inventories Chart

Echo Therapeutics Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Total Inventories

Get a 7-Day Free Trial

Echo Therapeutics Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Echo Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Echo Therapeutics (OTCPK:ECTE) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Echo Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2016 is

	Net-Net Working Capital Per Share (Q: Sep. 2016 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.173	+	0.75 * 0	+	0.5 * 0	-	7.363
-	0.08	-	0)	/	11.6359
=	-0.62

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Echo Therapeutics's Days Inventory for the three months ended in Sep. 2016 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2016 )	/	Cost of Goods Sold (Q: Sep. 2016 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Echo Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2016 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2016 )	/	Average Total Inventories (Q: Sep. 2016 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Echo Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2016 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2016 )	/	Revenue (Q: Sep. 2016 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Echo Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Echo Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Echo Therapeutics (Echo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Echo Therapeutics Inc (OTCPK:ECTE) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

99 Wood Avenue South, Suite 302, Iselin, NJ, USA, 08830

Website

http://www.echotx.com

Echo Therapeutics Inc is a medical device company with expertise in skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring system with potential use in the wearable health consumer and the diabetes outpatient market.

Executives

Michael M Goldberg	director	C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Uri Landesman	10 percent owner	230 PARK AVENUE, NEW YORK NY 10169
Platinum Partners Value Arbitrage Fund, Lp	10 percent owner	250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019
Mark Nordlicht	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Platinum Management (ny) Llc	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Platinum-montaur Life Sciences, Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Partners Liquid Opportunity Master Fund L.p.	10 percent owner	152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Liquid Opportunity Management (ny) Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Bernhardt Charles Thomas Iii	officer: Interim CFO	23 BIRCH ROAD, MALVERN PA 19355
Vincent D Enright	director	ONE CORPORATE CENTER, RYE NY 10580
William Grieco	director	830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067
Platinum Long Term Growth Vii, Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Robert F Doman	director, officer: EXEC. CHAIRMAN AND INTERIM CEO	C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887
Patrick T Mooney	director, officer: CEO AND PRESIDENT	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Christopher P. Schnittker	officer: CFO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540

Echo Therapeutics (Echo Therapeutics) Headlines

No Headlines